ImmuNe ParameTERs to Predict Immunotherapy REsponse and Toxicity (INTERPRET)

Part of paid clinical trials in Indianapolis, Indiana.

Sponsor
Indiana University
Study ID
NCT06900296
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Study Details

This is a prospective observational study that will collect blood samples at 1-10 timepoints related to initiation of immunotherapy. The study may collect samples before the start of immunotherapy and/or at clinically significant timepoints during immunotherapy treatment.

Key Dates

Start date
May 31, 2026
Status verified
Oct 2025
Primary completion
Apr 30, 2029
Completion
Apr 30, 2029

Study Design

Enrollment
100 participants (estimated)

Primary Outcome Measure

Quantification of plasma concentrations [ Time Frame: through study completion (i.e. up to 12 months) ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Indiana University Melvin and Bren Simon Comprehensive Cancer CenterIndianapolisIndiana46202
Ross Robinson
[email protected]
317-274-2744
Tyler Shugg, PharmD, PhD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Indianapolis, IN

By research site
Indiana University Melvin and Bren Simon Comprehensive Cancer Center· Indianapolis, IN

Related Studies